Literature DB >> 10450742

Proximal bile duct cancer: high resectability rate and 5-year survival.

B Launois1, J Terblanche, M Lakehal, J M Catheline, E Bardaxoglou, S Landen, J P Campion, F Sutherland, B Meunier.   

Abstract

OBJECTIVE: To review and update the authors' experience with resectional surgery for proximal bile duct carcinoma (Klatskin tumor) and assess the role of liver resection over the past 25 years.
BACKGROUND: Until recently, resection of proximal bile duct carcinoma was uncommon, with most patients undergoing palliative procedures. The authors adopted a radical surgical approach aimed at definitive cure in 1974. Recent reports suggest that resection improves outcome.
METHODS: The records of 40 of 94 patients (23 men, 17 women, age range 34-81 years) diagnosed with proximal bile duct carcinoma who underwent resection between 1968 and 1993 were reviewed. According to the Bismuth classification, there were five type I, four type II, 25 type III, and six type IV lesions; 11 patients underwent tumor resection alone, and 25 patients had combined tumor and liver resection (seven of these also underwent an associated regional vascular resection). In 3 patients, venous allografts were harvested from cadaveric donors and used to reconstruct the portal vein. Four patients underwent liver transplantation; in two, organ cluster-type resections including the liver with porta hepatitis and pancreas were performed.
RESULTS: The resectability rate in the more recent period of the study was 49.4%. Most type I, three (of four) type II, T in situ, T1a, T1b, and all stage 0 tumors were resected without hepatectomy. In the other subgroups of tumors, the main surgical procedure was hepatectomy. Thirty-day mortality was 12.5%. After tumor resection alone, survival at 1, 3, and 5 years was 81.8%, 45.5%, and 27.3%, respectively. After tumor resection and hepatectomy without vascular resection, 1-, 3-, and 5-year survival was 66.7%, 16.7%, and 6%, respectively. With vascular resection, survival rates were similar: 64%, 20%, and 4%, respectively.
CONCLUSION: The type of surgery required to achieve cure is closely related to tumor location, TNM classification, and staging. Increasing resectability through the use of hepatectomy improves survival and offers a chance of cure in patients with more advanced disease.

Entities:  

Mesh:

Year:  1999        PMID: 10450742      PMCID: PMC1420870          DOI: 10.1097/00000658-199908000-00018

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  31 in total

1.  [Approach to and use of the left hepatic duct in reparation of the common bile duct].

Authors:  J HEPP; C COUINAUD
Journal:  Presse Med       Date:  1956-05-23       Impact factor: 1.228

2.  Management strategies in resection for hilar cholangiocarcinoma.

Authors:  H Bismuth; R Nakache; T Diamond
Journal:  Ann Surg       Date:  1992-01       Impact factor: 12.969

3.  Prolonged palliation in carcinoma of the man hepatic duct junction.

Authors:  J Terblanche; S J Saunders; J H Louw
Journal:  Surgery       Date:  1972-05       Impact factor: 3.982

4.  [3 cases of typical hepatectomy of various indications].

Authors:  A Rohner
Journal:  Lyon Chir       Date:  1968 Jan-Feb

5.  Venous allografts: a useful alternative to venous autografts in digestive surgery.

Authors:  B Launois; G G Jamieson; G Maddern; S Landen; J P Campion; P Coeurdacier; E Bardaxoglou
Journal:  Aust N Z J Surg       Date:  1995-08

Review 6.  Surgical treatment in proximal bile duct cancer. A single-center experience.

Authors:  R Pichlmayr; A Weimann; J Klempnauer; K J Oldhafer; H Maschek; G Tusch; B Ringe
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

Review 7.  Malignant melanoma of the hepatic and common bile ducts. A case report and review of the literature.

Authors:  Y Deugnier; B Turlin; D Léhry; J R Pennarun; P Verger; B Launois; M P Ramée
Journal:  Arch Pathol Lab Med       Date:  1991-09       Impact factor: 5.534

8.  Outcomes after curative resections of cholangiocarcinoma.

Authors:  D M Nagorney; J H Donohue; M B Farnell; C D Schleck; D M Ilstrup
Journal:  Arch Surg       Date:  1993-08

9.  Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience.

Authors:  R Schoenthaler; T L Phillips; J Castro; J T Efird; A Better; L W Way
Journal:  Ann Surg       Date:  1994-03       Impact factor: 12.969

10.  Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.

Authors:  H A Pitt; A Nakeeb; R A Abrams; J Coleman; S Piantadosi; C J Yeo; K D Lillemore; J L Cameron
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

View more
  56 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  [Hilar cholangiocarcinoma -- results of en bloc resection of tumor and liver].

Authors:  G Otto; J Thies; M Hoppe-Lotichius; F Bittinger; M B Pitton; A Hadian
Journal:  Chirurg       Date:  2004-01       Impact factor: 0.955

3.  Reappraisal of hepatopancreatoduodenectomy as a treatment modality for bile duct and gallbladder cancer.

Authors:  Chang-Sup Lim; Jin-Young Jang; Seung Eun Lee; Mee Joo Kang; Sun-Whe Kim
Journal:  J Gastrointest Surg       Date:  2012-01-24       Impact factor: 3.452

4.  Prognostic factors in gallbladder and biliary tract cancer.

Authors:  Xóchitl Gómez-Roel; Oscar Arrieta; Eucario León-Rodríguez
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

5.  An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center.

Authors:  Elijah Dixon; Charles M Vollmer; Ajay Sahajpal; Mark Cattral; David Grant; Christopher Doig; Al Hemming; Bryce Taylor; Bernard Langer; Paul Greig; Steven Gallinger
Journal:  Ann Surg       Date:  2005-03       Impact factor: 12.969

6.  Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Alessandro Valdegamberi; Fabio Bagante; Francesca Bertuzzo; Simone Conci; Calogero Iacono
Journal:  J Gastrointest Surg       Date:  2013-09-19       Impact factor: 3.452

7.  Surgical treatment of hilar bile duct carcinoma: experience with 25 consecutive hepatectomies.

Authors:  Yoshifumi Kawarada; Bidhan C Das; Tatsushi Naganuma; Masami Tabata; Hiroki Taoka
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

8.  Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization.

Authors:  Seiji Kawasaki; Hiroshi Imamura; Akira Kobayashi; Terumasa Noike; Shiro Miwa; Shin-ichi Miyagawa
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

9.  Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate.

Authors:  Yasuji Seyama; Keiichi Kubota; Keiji Sano; Tamaki Noie; Tadatoshi Takayama; Tomoo Kosuge; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

10.  Resection of hilar cholangiocarcinomas: pivotal prognostic factors and impact of tumor sclerosis.

Authors:  Harald Puhalla; Thomas Gruenberger; Herwig Pokorny; Thomas Soliman; Fritz Wrba; Ulrike Sponer; Thomas Winkler; Meinhard Ploner; Markus Raderer; Rudolf Steininger; Ferdinand Mühlbacher; Friedrich Laengle
Journal:  World J Surg       Date:  2003-05-13       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.